Abcuro, founded with a mission to develop innovative treatments for autoimmune diseases and cancer, is a clinical-stage biotechnology company. The company's vision is to harness the precision targeting of highly cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1. Abcuro's leading product, ABC008, is an investigational monoclonal antibody designed to selectively deplete these cytotoxic cells, offering potential treatment for conditions like Inclusion Body Myositis (IBM), a chronic progressive disorder.
Notable figures affiliated with Abcuro include Mark Pruzanski, M.D., who serves as the Chairman of its Board of Directors. The company has made significant strides in advancing ABC008 through clinical trials, positioning it as a first-in-class therapeutic candidate. Abcuro's impact lies in its targeted approach to modulating immune responses, which holds promise for improving the lives of patients suffering from debilitating autoimmune diseases and certain cancers.
